Development tracks for cancer prevention markers

Disease Markers

Volumn 20, Issue 2, 2004, Pages 97-102

  Baker, Stuart G ^a   Kramer, Barnett S ^b   Prorok, Philip C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RESEARCH; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE MARKER; EARLY DIAGNOSIS; HUMAN; METHODOLOGY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

EID: 4344639162     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/309391     Document Type: Review

References (27)

1. J.A. Baron, et al., Calcium supplements for the prevention of colorectal adenomas, New England Journal of Medicine 340 (1999), 101-107.
2. S.G. Baker, Identifying combinations of cancer biomarkers for further study as triggers of early intervention, Biometrics 56 (2000), 1082-1087.
3. S.G. Baker, The Central Role of Receiver Operating Characteristic (ROC) Curves in Evaluating Tests for the Early Detection of Cancer, J. Natl Cancer Inst. 95(7) (Apr 2 2003), 511-515.
4. S.G. Baker, D. Erwin, B.S Kramer and P.C. Prorok, Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening, BMC Medical Research Methodology 3:4 (2003), (06 Mar 2003).
5. S.G. Baker and L.S. Freedman, Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example, Journal of the National Cancer Institute 87 (1995), 1137-1144.
6. S.G. Baker and B.S Kramer, Designing a genetic subset study for a randomized trial with a binary endpoint, BMC Medical Research Methodology 3(16) (2003).
7. S.G. Baker and B.S Kramer, A perfect correlate does not a surrogate make, BMC Medical Research Methodology 3(16) (2003).
8. S.G. Baker, B.S. Kramer and S. Srivastava, Markers for early detection of cancer: Statistical issues for nested case-control studies, BMC Medical Research Methodology 2 (2002), 4.
9. S.G. Baker, B.S. Kramer and P.C. Prorok, Statistical issues in randomized trials of cancer screening, BMC Medical Research Methodology 2 (2002), 11.
10. S.G. Baker, K.L. Lindeman and B.S. Kramer, The paired availability design for historical controls, BMC Medical Research Methodology 1 (2001), 9.
11. S.G. Baker and M.S. Tockman, Evaluating serial observations of precancerous lesions for further study as a trigger for early intervention, Statistics in Medicine 21 (2002), 2383-2390.
12. M. Buyse and G. Molenberghs, Criteria for the validation of surrogate endpoints in randomized experiments, Biometrics 54 (1998), 1014-1029.
13. A.J. Coldman, N. Philips and T.A. Pickles, Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity, Canadian Medical Association Journal 168 (2003), 31-35.
14. N.E. Day, Estimating the sensitivity of a screening test, Journal of Epidemiology and Community Health 39 (1985), 364-366.
15. N.E. Day and S.W. Duffy, Trial design based on surrogate end points - application to comparison of different breast screening frequencies, Journal of the Royal Statistical Society A 159(1) (1996), 49-60.
16. S. Duffy, et al., The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties, A collaborative evaluation, Cancer 95 (2002), 458-469.
17. T.R. Fleming and D.L. DeMets, Surrogate end points in clinical trials: Are we being misled? Annals of Internal Medicine 125 (1996), 605-613.
18. L.S. Freedman, B.I. Graubard and A. Schatzkin, Statistical validation of intermediate endpoints for chronic diseases, Statistics in Medicine 11 (1992), 167-178.
19. M.H. Gail, R. Pfeiffer, H.C. Houwelingen and R.J. Carroll, On meta-analytic assessment of surrogate outcomes, Biostatistics 3 (2001), 231-246.
20. P. RHolt, et al., Modulation of abnormal colonic epithelial cell proliferation and differentiation by low-fat dairy foods: a randomized controlled trial, J. Am Med. Assoc. 280 (1999), 1074-1079.
21. M.D. Hughes, V. Degruttola and S.L. Welles, Evaluating Surrogate Markers Acq Immun Def Synd 10 S1-S8(2) (1995).
22. M. King, et al., Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2 National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial, Journal of the American Medical Association 286 (2001), 2251-2256.
23. G. Molenberghs, et al., Statistical challenges in the evaluation of surrogate endpoints in randomized trial, Controlled Clinical Trials 23 (2002), 607-625.
24. A.S. Morrison, Intermediate determinants of mortality in the evaluation of screening, International Journal of Epidemiology 20 (1991), 642-650.
25. E.F. Petricoin, et al., Use of proteomic patterns in serum to identify ovarian cancer, The Lancet 359 (2002), 572-577.
26. L. Peron, L. Moore, I. Bairati, P. Bernard and F. Meyer, PSA screening and prostate cancer mortlaity, Canadian Medical Association Journal 166 (2002), 586-591.
27. M.H. Schiffman et al., Human popillomavirus and cervical intraepithelial neoplasia response, Journal of the National Cancer Institute 85 (1993), 1868-1870.